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Abstract
Background: Carcinoid tumours are well-differentiated neuroendocrine tumours with secretory
properties. Although fairly rare, they are the most common malignancy seen to affect the distal
small bowel. Presentation is often non-specific with symptoms mimicking those of irritable bowel
syndrome. Given this, the condition is often diagnosed late following disease progression, by which
time the prognosis is poor.
Case presentation: A 74 year old Caucasian lady presented with a two week history of loose
stools, nausea and one episode of vomiting. This sub-acute presentation occurred on a background
of a four year history of intermittent abdominal pain and bloating, previously diagnosed as irritable
bowel syndrome. CT scans identified dilated loops of small bowel proximal to a spiculated mass in
the region of the terminal ileum. This ileal lesion was removed at laparotomy and identified as a
carcinoid tumour.
Conclusion: This case highlights the issue of misdiagnosis of intestinal malignancy as the benign
condition of irritable bowel syndrome. There have been several other references to this
happenstance in the literature, and the problem is reflected in the percentage of patients with
widespread disease at the time of diagnosis. Prognosis in this condition can be dramatically
improved with early diagnosis, and surgical management at this stage is often curative. For this
reason it is imperative to keep this differential diagnosis in the back of one's mind when assessing
patients presenting with symptoms of intermittent partial bowel obstruction. The clinical
presentation of this tumour, along with investigation and management of these cases, is discussed
here.
Background
Midgut carcinoids are generally well-differentiated neu-
roendocrine tumours with secretory characteristics. An
occurrence rate within the small intestine of 1 in 300 has
been reported at autopsy, making it the most common
distal small bowel malignancy [1]. In addition, when con-
sidering tumours of the jejunum and ileum, multicentric-
ity occurs in 26–30% of cases [2]. These are also the most
common tumours affecting the appendix accounting for
80% of appendiceal growths; however these are usually
small, non-metastatic and cured by simple appendicec-
tomy [3]. There is also a low incidence of metastasis from
tumours within the small bowel; in spite of this, liver
metastases are often present at the time of diagnosis as
patients are identified late in the disease [4].
Published: 22 January 2009
Cases Journal 2009, 2:78 doi:10.1186/1757-1626-2-78
Received: 16 September 2008
Accepted: 22 January 2009
This article is available from: http://www.casesjournal.com/content/2/1/78
© 2009 Wilson; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Cases Journal 2009, 2:78 http://www.casesjournal.com/content/2/1/78
Page 2 of 4
(page number not for citation purposes)
Case presentation
A 74 year old lady presented to the emergency department
following a fall. On further questioning she reported a
two week history of loose stools, mild abdominal pain
and one episode of vomiting. These symptoms occurred
on a four year background of intermittent abdominal pain
and bloating for which she had been referred to a surgical
outpatient clinic three years previously. Following a nor-
mal gastroscopy and colonoscopy she was diagnosed with
irritable bowel syndrome.
Physical examination showed abdominal distension with
generalised tenderness and active bowel sounds. She was
clinically dehydrated and blood tests revealed a low potas-
sium of 2.9 and elevated urea of 12.9. The patient under-
went an abdominal CT scan which identified dilated
loops of small bowel proximal to a spiculated mass in the
region of the terminal ileum with mesenteric lymph
nodes. Multiple small lesions within the liver were also
noted. [Figure 1: CT showing dilated loops of bowel, spic-
ulated lesion and mesenteric lymph node enlargement.
Figure 2: CT showing liver lesion (arrow)]
At laparotomy the surgical team located the lesion within
an ischaemic terminal ileum. They also found significant
mesenteric lymphadenopathy. The team carried out a
small bowel resection with ileo-caecal anastomosis. At
histology the lesion within the terminal ileum was identi-
fied as a carcinoid tumour measuring 2 cm, with
mesenteric nodal metastasis in the proximal ileum. The
patient made a good post-operative recovery and went on
for further assessment to identify metastatic disease.
Discussion
The term carcinoid was first used to describe 'hormonally
active' tumours in 1907 by Oberndorfer [5]. They are
derived from stem cells in the gut wall and have been clas-
sified depending on the location within the primitive gut
from which they arise [6]. Tumours of the bronchus,
stomach, proximal duodenum and pancreas are derived
from the foregut; the midgut gives rise to tumours found
in the second portion of the duodenum, the jejunum, the
ileum and the right colon, while those of the hindgut
include the transverse colon, descending colon, and rec-
tum. Given the tumour site in this case, further discussion
will refer to midgut tumours only.
Clinical presentation can be with non-hormonal symp-
toms secondary to tumour bulk and local reaction, or with
symptoms of a functioning tumour, described as 'carci-
noid syndrome'. Tumours arising in the small intestine
are often silent until late in the disease and are thus locally
advanced at presentation [7]. Non-hormonal symptoms
are most commonly secondary to partial mechanical
obstruction of the small bowel with patients complaining
of intermittent vague abdominal symptoms such as pain
and distention. It is for this reason that patients with car-
cinoids are frequently misdiagnosed with irritable bowel
syndrome [1]. These obstructive features may be due to
peritumoral fibrosis or invasion, causing direct luminal
strictures, or secondary to desmoplastic reaction leading
to ischaemic changes [8]. Other non-hormonal symptoms
include anorexia, weight loss, fatigue and occasionally a
palpable abdominal mass is noted.
The term 'carcinoid syndrome' is used to describe the hor-
monal manifestations of carcinoid tumours and occurs
Abdominal CT scan demonstrating dilated loops of bowel, a  spiculated lesion in the terminal ileum and mesenteric lymph  node enlargement Figure 1
Abdominal CT scan demonstrating dilated loops of 
bowel, a spiculated lesion in the terminal ileum and 
mesenteric lymph node enlargement.
Abdominal CT scan showing liver lesion Figure 2
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secondary to the secretion of serotonin, tachykinins,
bradykinins and prostaglandins. Midgut carcinoid
tumours are typically seen to secrete serotonin [9]. Recent
consensus is that functionally active tumours account for
around 20–30% in this group, higher than previously
thought [4]. The syndrome occurs when vasoactive sub-
stances from tumour secretion enter the systemic circula-
tion. In the case of small bowel tumours this can only
occur in the presence of multiple hepatic metastases, as
substances such as serotonin usually undergo hepatic deg-
radation to non-active substrates. The symptoms of carci-
noid syndrome and their prevalence are outlined in figure
3: Prevalence of symptoms occurring in carcinoid syn-
drome.
Investigation of these symptoms is best done with a mul-
timodality approach including biochemical investigation,
radiological and nuclear imaging, and finally histological
confirmation where possible. In patients presenting with
symptoms of carcinoid syndrome urinalysis can be carried
out for elevated 5-HIAA levels. Chromogranin A can also
be used as a sensitive marker to identify midgut carcinoid
tumours, however, specificity may be low [10]. The most
sensitive imaging techniques depend on the site of the
tumour but may include CT, MRI and ultrasound scan-
ning in combination with endoscopy and small bowel
studies. Where a gastrointestinal neuroendocrine tumour
is suspected or confirmed, somatostatin receptor scintig-
raphy is routinely used to locate both primary and sec-
ondary deposits for staging of the disease. Somatostatin
receptor type 2 is expressed by 80% of carcinoid tumours
allowing this mode of imaging a sensitivity of up to 90%
for midgut tumours [11].
Given that the majority of these tumours are well-differen-
tiated, following an indolent course, prognosis is surpris-
ingly unfavorable. This can mainly be attributed to the
fact that the majority of cases present so late by which
time spread has invariably occurred. Survival correlates
closely to stage at presentation with a 5-year survival of
65% reported for localized/regional disease and 36% if
distant metastases are present [4].
The principal management approach in these cases is sur-
gical resection of the primary lesion and is the only cura-
tive option. With smaller lesions (< 1 cm) local resection
is usually adequate. However, with lesions over 1.5 cm
there is a high risk of recurrence and thus segmental resec-
tion is required with extensive clearance of the associated
mesenteric lymph nodes [1]. Surgery has been shown to
Bar chart plotting the prevalence of symptoms and signs occurring in carcinoid syndrome Figure 3
Bar chart plotting the prevalence of symptoms and signs occurring in carcinoid syndrome. Data taken from http:/
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be of benefit even in patients with metastatic disease, both
to gain symptomatic relief and improve survival [4].
Further management of patients with liver metasteses is
still controversial. Treatment options include resection of
the hepatic tumours, or hepatic artery embolisation
(HAE) as an alternative to surgery. There are a number of
studies in the literature looking into the benefits of
hepatic resection with regards to both symptomatic relief
and prolonged survival rates. Que et al. report a 90%
symptomatic response with liver resection and state that
debulking extends survival; however recurrence is
expected [12]. Other authors have also reported the possi-
bility of a prolonged survival time, but it should be
pointed out that in this study the comparison group were
those patients with inoperable disease who may have
therefore had more advanced underlying disease [13].
Similar benefits have been demonstrated using HAE with
palliation of both hormonal and pain symptoms [14].
Although advantages have been seen with these
approaches it should be noted that, given the rare nature
of this condition, population groups within the research
have been small and studies have generally been retro-
spective.
Other possibilities for symptomatic management of
patients with hormonal symptoms include biotherapy
using drugs such as somatostatin analogs. These have
been shown not only to provide symptomatic improve-
ment in 70–80% but also to stabilize tumour growth [4].
This therapy is therefore used as first-line treatment in
inoperable functioning tumours and to avoid a carcinoid
crisis in those undergoing surgery.
Conclusion
Despite the rarity of this condition, carcinoid tumours are
the most common lesion seen to affect the distal small
intestine. Unfortunately, in the majority of cases presenta-
tion is often late in the disease and metastases are there-
fore regularly seen at the time of diagnosis. Analysis of
five-year survival rates has identified several factors associ-
ated with a poor prognosis including multiple liver
metasteses, the presence of carcinoid syndrome and high
levels of hormonal markers [15]. Given that the clinical
presentation is often with non-specific abdominal symp-
toms, diagnosis can be difficult and patients are fre-
quently misdiagnosed with irritable bowel syndrome [1].
Surgical resection is the only curative management option
and there is evidence to support a better prognosis when
lesions are small. Consequently it is important to keep
this differential diagnosis in the back of one's mind when
assessing patients presenting with symptoms of intermit-
tent partial bowel obstruction to improve early diagnosis
and outcomes in this patient group.
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